Listed by the USPTO as SZPERKA, MICHAEL EDWARD
Tech Center 1600 • Art Units: 1600 1641 1644
This examiner grants 63% of resolved cases
SZPERKA, MICHAEL EDWARD is assigned to Tech Center 1600 and art unit 1600. Across 958 resolved cases, the profile shows a 62.6% allowance rate and a 37.5% interview lift. The median days to allowance is 1120. The case volume supports using the pattern for planning, and the interview figure indicates that examiner engagement may be particularly relevant when addressing substantive issues.
The leading companies are Alexion Pharmaceuticals Inc., Novartis AG, and The Regents of the University of California. The associated firms are Casimir Jones, S.C., FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, and MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP. The client and firm names point to pharmaceutical and university-related experience.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18655058 | FACTOR XI ANTIBODIES AND METHODS OF USE | Non-Final OA | NOVARTIS AG |
| 18391485 | METHODS OF TREATING CHRONIC SPONTANEOUS URTICARIA USING LIGELIZUMAB | Non-Final OA | Novartis AG |
| 18242868 | FACTOR X BINDERS ENHANCING FX ACTIVATION | Final Rejection | Novo Nordisk A/S |
| 18467429 | MacrophageexpressingChimeric Antigen Receptor for Binding FAP antigen and its construction method and uses thereof | Final Rejection | Zhejiang University |
| 17040476 | TRANS-ANTIGEN TARGETING IN HETEROGENEOUS CANCERS AND METHODS OF USE THEREOF | Final Rejection | The Regents of the University of California |
| 18252442 | NOVEL LINKERS OF MULTISPECIFIC ANTIGEN BINDING DOMAINS | Final Rejection | AMGEN INC. |
| 18556998 | METHODS FOR REDUCING LOW MOLECULAR WEIGHT SPECIES OF RECOMBINANTLY-PRODUCED PROTEINS | Non-Final OA | AMGEN RESEARCH (MUNICH) GmbH |
| 16755370 | METHOD FOR SELECTING HIGHLY EFFICIENT STEM CELL, USING PROTEIN MARKER GRP78 | Non-Final OA | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 18060215 | COMPOSITIONS AND METHODS FOR PURIFYING ALPHA-1 ANTITRYPSIN USING PEPTIDE LIGANDS | Non-Final OA | North Carolina State University |
| 18250106 | COMBINATION VACCINE FOR PROTECTING SWINE AGAINST VARIOUS DISORDERS | Non-Final OA | Intervet Inc. |
| 18555910 | METHOD AND COMPOSITION | Non-Final OA | Oxford University Innovation Limited |
| 18532709 | COMPLEMENT FACTOR H ANTIBODIES | Non-Final OA | Duke University |
| 18544966 | EVALUATION, ASSAYS AND TREATMENT OF PKALMEDIATED DISORDERS | Final Rejection | Takeda Pharmaceutical Company Limited |
| 18526959 | HUMAN ANTIBODY DRUG CONJUGATES AGAINST TISSUE FACTOR | Non-Final OA | Genmab A/S |
| 18504037 | CHIMERIC RECEPTORS AND METHODS OF USE THEREOF | Non-Final OA | Senti Biosciences, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy62.6% of resolved applications examined by Michael Edward Szperka were allowed (958 resolved cases), compared with 37.3% across Art Unit 1600 over the last five years.
This examiner's interview lift is +37.5 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Michael Edward Szperka took 1,120 days on average from filing to allowance.
Michael Edward Szperka examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
